论文部分内容阅读
目的探讨α-干扰素针肌肉注射协同重组干扰素α-2b栓治疗高危型乳头瘤病毒(HPV)感染。方法选择妇产科门诊治疗宫颈高危型HPV感染患者68例,随机分为联合组和对照组,每组均为34例。两组患者均于月经结束后3 d予以重组干扰素α-2b栓阴道内放置,1枚/晚,连用10 d,下次月经后开始下一个疗程,连用3个疗程。联合组患者在此基础上予以α-干扰素1 000 000U肌内注射,1次/隔天,连用10d,下次月经后开始下一个疗程,连用3个疗程。观察并记录两组患者临床疗效及不良反应,比较治疗后随访半年和1年后HPV的转阴率。结果治疗3个疗程后,联合组患者临床总有效率(94.12%)明显优于对照组(76.47%)(χ2=4.22,P<0.05)。对照组和联合组治疗中分别出现不良反应4例和10例,症状均较轻微,两组患者不良反应发生率比较差异无统计学意义(χ2=3.24,P>0.05)。治疗后随访半年和1年后,联合组的HPV的转阴率分别为96.88%和90.63%,均明显高于对照组的73.08%和65.38%(χ2=4.98或5.57,P<0.05)。结论α-干扰素针肌肉注射协同重组干扰素α-2b栓治疗高危型HPV感染的临床效果较显著,安全性较佳,且其中远期临床效果亦较佳,能更有效提高HPV的转阴率。
Objective To investigate the treatment of high-risk papillomavirus (HPV) infection by intramuscular injection of α-interferon combined with recombinant interferon α-2b suppository. Methods Select obstetrics and gynecology outpatient treatment of high-risk cervical HPV infection in 68 patients were randomly divided into combined group and control group, 34 cases in each group. Two groups of patients were 3 days after the end of menstruation to be recombinant interferon α-2b suppositories placed in the vagina, 1 / night, once every 10 days, the next menstruation began the next course of treatment, once every 3 courses. Combined group of patients on this basis to be given α-interferon 1 000 000U intramuscular injection, 1 / every other day, once every 10 days, the next menstruation began the next course of treatment, once every 3 courses. The clinical efficacy and adverse reactions of the two groups were observed and recorded. The negative rates of HPV after 6 months and 1 year follow-up were compared. Results After 3 courses of treatment, the total effective rate (94.12%) in the combined group was significantly better than that in the control group (76.47%) (χ2 = 4.22, P <0.05). There were 4 adverse reactions and 10 mild symptoms in the control group and the combination group, respectively. There was no significant difference in the incidence of adverse reactions between the two groups (χ2 = 3.24, P> 0.05). After six months and one year follow-up, the negative conversion rates of HPV in the combined group were 96.88% and 90.63%, respectively, which were significantly higher than those in the control group (73.08% and 65.38%, χ2 = 4.98 or 5.57, P <0.05). Conclusion Intra-a-interferon intramuscular injection of interferon α-2b suppository is effective in treating high-risk HPV infection, and its safety is better, and its long-term clinical effect is also better, which can effectively improve the incidence of HPV negative conversion rate.